Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction earnings

This article was originally published in The Tan Sheet

Executive Summary

OTC net sales advanced 18.3 percent to $234.3 million in 2007, "in line with e-commerce trends, but below our expectations due to increased marketing costs in paid search and portals," the e-commerce marketer announces during a Feb. 6 analyst meeting. Gross profit for OTCs during the year advanced 19.8 percent to $69.8 million. For the fourth quarter, OTC revenues were up 17.4 percent to $65.8 million, while gross profit for the period advanced 31.6 percent to $20.5 million.'s net sales for the full year grew 7.2 percent to $445.7 million, though the firm experienced a $9 million loss during the quarter, an improvement over a loss of $13 million last year. In 2008, the company plans to fuel top-line revenue growth in part by driving OTC sales up 20 percent year-over-year, the company says...

You may also be interested in...

Rite OTC site will host an online Rite Aid OTC store slated to launch this year, the companies say Sept. 4. Camp Hill, Pa.-based Rite Aid will receive rights to all Rx drugs ordered online for in-store pickup and will pay $10 million. "Having our own online OTC store and being able to market directly" to the pharmacy chain's customer base "is an important next step in our digital strategy," says Rite Aid Chief Operating Officer Rob Easley. Dawn Lepore, CEO of Bellevue, Wash.-based, says she expects increased sales as "Rite Aid will develop marketing programs to drive traffic to the new site." The e-retailer's 2007 net sales, announced in February, were below expectations due to increased marketing costs (1"The Tan Sheet" Feb. 11, 2008, In Brief)

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts